2024
Obesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics
Santoro N, Galderisi A, Caprio S. Obesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics. 2024, vol1:608-vol1:616. DOI: 10.1201/9781003437734-70.ChaptersNonalcoholic fatty liver diseaseType 2 diabetesInsulin resistanceAdolescent obesityAssociated with precocious pubertyDevelopment of prediabetesCardiometabolic risk factorsPathogenesis of insulin resistanceFatty liver diseasePrecocious pubertyClinical peculiaritiesPediatric obesityLiver diseaseRisk factorsGlobal health challengeMetabolic disordersObesityFatty liverPathological complicationsPotential mechanismsInsulinHealth challengesChildrenComplicationsDyslipidemia
2023
Obesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics
Santoro N, Galderisi A, Caprio S. Obesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics. 2023, 608-616. DOI: 10.1201/9781003437673-70.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseType 2 diabetesInsulin resistanceAdolescent obesityCardiometabolic risk factorsMajor global health challengeFatty liver diseaseDevelopment of prediabetesGlobal health challengeClinical peculiaritiesFatty liverLiver diseasePediatric obesityRisk factorsPrecocious pubertyMetabolic disordersPathological complicationsObesityHealth challengesPsychosocial conditionsPotential mechanismsDiabetesEarly ageChildrenDyslipidemia
2022
Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase II study
Yadav Y, Dunagan K, Khot R, Venkatesh S, Port J, Galderisi A, Cobelli C, Wegner C, Basu A, Carter R, Basu R. Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase II study. Diabetes Obesity And Metabolism 2022, 24: 881-890. PMID: 35014156, PMCID: PMC9135169, DOI: 10.1111/dom.14646.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseLiver fat fractionFatty liver diseaseMagnetic resonance imagingMean changePlacebo groupPrimary outcomeLiver diseasePresence of NAFLDSignificant between-group differencesPhase II studyPhase 2 studyKey inclusion criteriaType 2 diabetesBetween-group differencesShort-term treatmentBiopsy positiveII studyNonalcoholic steatohepatitisWeek 12Liver steatosisHepatic fatInsulin sensitivityAZD4017Liver enzymes
2019
Chapter 11 Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Pathophysiologic Links and Potential Implications
Galderisi A, Martino M, Santoro N. Chapter 11 Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Pathophysiologic Links and Potential Implications. 2019, 91-99. DOI: 10.1016/b978-0-323-55138-0.00011-5.BooksNonalcoholic fatty liver diseaseFatty liver diseaseType 2 diabetesLiver diseasePediatric nonalcoholic fatty liver diseasePathophysiology of NAFLDEnd-stage liver diseaseIndependent risk factorPathophysiologic linkCommon complicationSimple steatosisPediatric obesityInsulin resistanceRisk factorsType 2Disease severityDiseaseDiabetesWide spectrumComplicationsPotential implicationsSteatosisObesityPathophysiologySeverity
2018
Ethnicity and Common Genetic Variants Modulate Nonalcoholic Fatty Liver Disease (NAFLD) Metabolic Phenotype in Obese Youth
TRICO D, CAPRIO S, UMANO G, GALDERISI A, MATA M, NOUWS J, PIERPONT B, KIM G, SANTORO N. Ethnicity and Common Genetic Variants Modulate Nonalcoholic Fatty Liver Disease (NAFLD) Metabolic Phenotype in Obese Youth. Diabetes 2018, 67 DOI: 10.2337/db18-313-or.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseasePediatric nonalcoholic fatty liver diseaseType 2 diabetesInsulin resistanceObese adolescentsInsulin sensitivityPrevalence of NAFLDHigher C-peptide levelsOral glucose tolerance testAfrican AmericansC-peptide levelsHigh fasting glucoseFatty liver diseaseGlucose tolerance testLower insulin sensitivityMajor risk factorZ-score BMIHepatic fat contentStrongest predictorCommon gene variantsFasting GlucoseNAFLD developmentGlucose toleranceLiver diseaseTolerance test